Gerald L. Andriole, M Deltasone online .D., E. David Crawford, M.D., Robert L. Grubb, III, M.D., Saundra S. Buys, M.D., David Chia, Ph.D., Timothy R. Church, Ph.D., Mona N. Fouad, M.D., Edward P. Gelmann, M.D., Paul A. Kvale, M.D., Douglas J. Reding, M.D., Joel L. Weissfeld, M.D., Lance A. Yokochi, M.D., Barbara O'Brien, M.P.H., Jonathan D. Clapp, B.S., Joshua M. Rathmell, M.S., Thomas L. Riley, B.S., Richard B. Hayes, Ph.D., Barnett S. Kramer, M.D., Grant Izmirlian, Ph.D., Anthony B. Miller, M.B., Paul F. Pinsky, Ph.D., Philip C. Prorok, Ph.D., John K. Gohagan, Ph.D., and Christine D. Berg, M.D. There has been simply no comprehensive assessment of the trade-offs between risks and benefits. Despite these uncertainties, PSA screening offers been adopted by many patients and doctors in the usa and other countries.
To assess the effects of treatment in the frequency of incontinence, we used generalized estimating equations with bad binomial models, with adjustment for clinical site and the baseline and 6-month outcomes treated as repeated actions. In a sensitivity evaluation, we also used the nonparametric Wilcoxon rank-sum test to compare %age adjustments in the regularity of incontinence. The effects of treatment on the %age change in weight from baseline to six months were assessed by using linear mixed models adjusted for site. Attrition in weight-loss research commonly masks regained excess weight. To handle this potential source of bias, we utilized multiple-imputation solutions to impute missing pounds data at six months, on the assumption of no change from baseline normally among dropouts.